GC Determination of Cisplatin in Serum and Urine of Cancer Patients after Chemotherapy as Platinum (II) Pyrrolidinedithiocarbamate Chelate

A gas chromatographic procedure has been developed for determination of cisplatin from pharmaceutical preparation, serum and urine after chemotherapy of cancer patients as platinum(II) pyrrolidinedithiocarbamate chelate. The elution was carried from the column DB-1701 (30 m × 0.32 mm i.d.) coupled with FID detection. Cu(II), Ni(II), Co(III), Mn(II), Fe(III), Zn(II) and VO(II) when present together with Pt(II) separated completely and did not affect the determination of platinum. The linear calibration curve for platinum (II) was within 1–30 μg mL^?1 with a detection limit of 300 ng mL^?1. The amount of cisplatin detected from serum and urine was 250–325 and 20–116 ng mL^?1 with relative standard deviations (RSD) of 0.8–1.2%, and 0.9–1.2%. The % recovery of Pt from serum and urine by standard addition was 98 and 98.2% with RSD 1.4 and 1.1%.